Teva Pharmaceutical Industries Limited

NYSE:TEVA 株式レポート

時価総額：US$36.9b

Teva Pharmaceutical Industries 配当と自社株買い

配当金 基準チェック /06

Teva Pharmaceutical Industries現在配当金を支払っていません。

主要情報

0%

配当利回り

n/a

バイバック利回り

総株主利回りn/a
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向0%

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブ更新 • Jul 21

TEVA: Fairly Valued Outlook Will Weigh Vitiligo Data And Biosimilar Expansion

Analysts have lifted their fair value estimate for Teva Pharmaceutical Industries from about $21.53 to roughly $33.08, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples, along with recent price target increases across several firms and renewed confidence in the vitiligo program despite short term share price weakness. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries has centered on how investors should think about valuation relative to execution risk, particularly around the vitiligo program and the timing of clinical milestones.
ナラティブ更新 • Jul 07

TEVA: Vitiligo Readout And Neuroscience Expansion Are Expected To Drive Upside

Analysts have raised their fair value estimate for Teva Pharmaceutical Industries from $45.00 to about $48.72, citing updated assumptions around revenue growth, profit margins, and future P/E. These changes align with a series of recent price target increases across the Street.
Seeking Alpha • Jun 28

Teva Pharmaceutical's Innovative Shift Continues With Ecopipam Addition

Summary Teva is transitioning from generics to high-margin branded drugs, underpinned by debt reduction and renewed M&A activity. Ecopipam, acquired via Emalex, adds a first-in-class asset for pediatric Tourette syndrome, with a risk-adjusted NPV of $1.49 billion. TEVA’s financial health is improving, with long-term debt halved and robust cash generation, but 2026 revenue is expected to decline 2.65–4.97% year-over-year. I maintain a Hold rating on TEVA, as current valuation already prices in ambitious revenue growth and pipeline execution risks remain. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 23

TEVA: Neuroscience Pivot And Vitiligo Readout Timing May Support 2026 Repricing

Teva Pharmaceutical Industries' analyst price target has been adjusted slightly to $40.90, with analysts pointing to recent stock underperformance tied to macro factors and updated vitiligo trial timelines, while maintaining underlying confidence in the pipeline and business fundamentals. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries highlights a mix of optimism about the company’s pipeline execution and caution around near term headlines and timing.
分析記事 • Jun 21

Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after a recent share price pullback, with the stock closing at $31.48. Investors are assessing how the current valuation lines up with the company’s fundamentals. See our latest analysis for Teva Pharmaceutical Industries. The recent 7 day share price return, down 9.1%, and 1 month share price return, down 7.6%, contrast with a 1 year total shareholder return of 85.7% and 3 year total shareholder return above 3x. This suggests that...
ナラティブ更新 • Jun 08

TEVA: Neuroscience Pipeline And Branded Shift May Support 2026 Multiple Reappraisal

Teva Pharmaceutical Industries' analyst price target has been adjusted from $40.27 to $41.27, as analysts factor in updated assumptions for revenue growth, profit margins and future P/E, supported by a series of recent price target increases from major research firms. Analyst Commentary Recent price target revisions for Teva Pharmaceutical Industries cluster tightly in favor of higher valuations, with several large firms, including JPMorgan, lifting their targets by between US$1 and US$6.
ナラティブ更新 • May 25

TEVA: Focused R&D In Neuroscience And Immunology Will Support 2026 Multiple Reappraisal

Analyst price targets on Teva Pharmaceutical Industries have edged higher, with the updated fair value estimate moving from about $40.09 to $40.27 as analysts factor in recent target increases and their views on the company’s R&D focus, core therapeutic areas, biosimilars business, and capital deployment plans. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries points to a cluster of higher price targets, with several bullish analysts updating their models after discussions with management about research priorities, therapeutic focus, biosimilars, and capital deployment.
ナラティブ更新 • May 04

TEVA: Neuroscience And Immunology Pipeline Will Drive 2026 Multiple Reappraisal

Analysts lifted the Teva Pharmaceutical Industries price target to $40.09 from $38.18, citing updated assumptions that point to higher revenue growth expectations, a slightly lower projected profit margin, and a higher future P/E multiple. This view is supported by recent research notes highlighting management's R&D focus, build out in core therapeutic areas, biosimilars vision, and capital deployment plans.
ナラティブ更新 • Apr 16

TEVA: Neuroscience And Immunology R&D And Biosimilars Will Shape 2026 Reappraisal

Analysts have nudged their Teva Pharmaceutical Industries price targets higher, with the model fair value moving from $37.82 to $38.18. This change is supported by updated views on the company's R&D focus in neuroscience and immunology, its biosimilars plans, capital deployment, and the evolving outlook for partnered assets such as duvakitug.
新しいナラティブ • Apr 09

Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine

Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?
ナラティブ更新 • Apr 02

TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal

Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.
ナラティブ更新 • Mar 18

TEVA: 2026 Neuroscience And Immunology Pipeline Progress Will Drive Bullish Outlook

Teva Pharmaceutical Industries' analyst price target is modestly higher, with recent $1 to $9 upward revisions tied to analysts' expectations for R&D progress in neuroscience and immunology, a growing biosimilars presence, and stronger cash generation that supports a slightly richer forward P/E multiple. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries focus on how the pipeline, cash generation, and balance sheet shape both upside potential and execution risks.
ナラティブ更新 • Mar 04

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.
ナラティブ更新 • Feb 18

TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook

Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.
ナラティブ更新 • Feb 04

TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook

Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.
ナラティブ更新 • Jan 20

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Should Support Re Rating

Narrative Update Analysts have lifted their price target range for Teva Pharmaceutical Industries toward the mid US$30s, reflecting updated assumptions on fair value, profit margins, and future P/E as they point to affordable medicines and potential R&D catalysts around 2026 as key drivers of sentiment. Analyst Commentary Recent street research points to a more constructive tone around Teva Pharmaceutical Industries, with higher price targets tied to its focus on affordable medicines and potential R&D catalysts around 2026.
ナラティブ更新 • Jan 06

TEVA: Shares Will Hold Steady As Q3 Trends Support Balanced Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries higher to about US$24, citing recent Q3 pricing and volume trends for key drugs and consistent expectations for earnings across commercial-stage biopharma names. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$24 price target as a reflection of steadier execution on key drugs, with recent Q3 pricing and volume trends supporting their valuation framework.
ナラティブ更新 • Dec 22

TEVA: Shares Will Trade Sideways As IRA Pricing Clarity Drives Relief Rally

Analysts have raised their fair value estimate for Teva Pharmaceutical Industries to approximately $32.77 from about $28.61, citing recent price target increases to the mid 20 dollar range, expectations for stable Q3 performance, and a potential relief rally tied to upcoming Austedo IRA pricing clarity. Analyst Commentary Recent Street research reflects a generally constructive stance on Teva, with price targets moving higher in anticipation of stable near term execution and clearer visibility on Austedo economics under the Inflation Reduction Act.
ナラティブ更新 • Dec 08

TEVA: Shares Will Trade Sideways As Drug Pricing Clarity Supports Margins

Analysts have nudged their average price target for Teva Pharmaceutical Industries higher from approximately $27.90 to about $28.60, citing stable near term earnings expectations, improving profit margin assumptions, and a potential relief rally tied to clarity on Austedo pricing under the IRA framework. Analyst Commentary Bullish analysts highlight that recent price target increases reflect growing confidence in Teva's ability to execute on its turnaround strategy and sustain earnings stability, even as broader biopharma peers face mixed revisions.
ナラティブ更新 • Nov 24

TEVA: Shares Will Rally As IRA Drug Pricing Clarity Approaches

Teva Pharmaceutical Industries' analyst price target has been raised modestly, with analysts citing improved key drug performance and potential relief as regulatory pricing clarity emerges. This reflects a shift from approximately $27.45 to $27.90 per share.
分析記事 • Nov 13

We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative

Shareholders appeared to be happy with Teva Pharmaceutical Industries Limited's ( NYSE:TEVA ) solid earnings report...
分析記事 • Nov 12

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shares have been powering on, with...
ナラティブ更新 • Nov 07

TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears

Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.
ナラティブ更新 • Oct 23

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.
ナラティブ更新 • Oct 09

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

Teva Pharmaceutical Industries saw its analyst price target increase modestly from $23.89 to $24.22 per share. Analysts cite anticipated relief rallies and favorable prospects for the company's Austedo pricing strategy.
ナラティブ更新 • Sep 25

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89. What's in the News UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.
User avatar
新しいナラティブ • Apr 23

Generics And Biosimilars Pipeline And Expansion Will Define Progress

The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.
Seeking Alpha • Feb 28

Teva Pharmaceutical: A Risky Bet With Potential Upside

Summary Teva Pharmaceutical faces challenges with high debt, legal issues, and pricing pressure, but is shifting focus to higher-margin biosimilars and specialty drugs. Despite trading at a low 6.56x forward earnings, Teva's high debt-to-EBITDA ratio and declining earnings are significant concerns. The company's push into biosimilars is promising, but execution and market competition will be critical for success. Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and profitability issues. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity

Summary Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperformed, and a desirable entry point for long-term investors. Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027. Teva's aggressive debt reduction enhances financial stability, paving the way for future shareholder-friendly activities like dividends or share repurchases. A 12-month price target of $25/share, 10x FY 2025 non-GAAP EPS estimates seems achievable should Teva outperform lowered EPS and sales estimates. Read the full article on Seeking Alpha

決済の安定と成長

配当データの取得

安定した配当: TEVAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: TEVAの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Teva Pharmaceutical Industries 配当利回り対市場
TEVA 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (TEVA)0%
市場下位25% (US)1.3%
市場トップ25% (US)4.0%
業界平均 (Pharmaceuticals)1.9%
アナリスト予想 (TEVA) (最長3年)0%

注目すべき配当: TEVAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: TEVAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: TEVA US市場において目立った配当金を支払っていません。

株主配当金

キャッシュフローカバレッジ: TEVAが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/29 01:46
終値2026/07/29 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Teva Pharmaceutical Industries Limited 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。44

アナリスト機関
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Glen SantangeloBarclays